James M Daly
CIK 1560782 · EVP, Chief Commercial Officer · last filed 2026-07-16
James M Daly is an EVP, Chief Commercial Officer who has filed 81 SEC Form 4 insider transactions across 7 companies since 2012. The most recent filing shows the insider was granted $12.5K of CYTK on Jul 16, 2026. Across all open-market trades the lifetime net is −$41.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.61M
7
81
-$41.76M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CYTK | Director | 3,390 | $76.76 | $260.2K | $0 | 5 | 2026-07-16 |
| MDGL | Director | 3,081 | $510.04 | $1.57M | -$13.59M | 10 | 2026-06-18 |
| ACAD | Director | 12,148 | $29.21 | $354.8K | -$3.15M | 16 | 2026-06-01 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Director | 20,503 | — | — | -$2.29M | 11 | 2023-08-15 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Director | 109,873 | $0.07 | $8.2K | $0 | 13 | 2023-01-05 |
| CHIMERIX INC (CMRX) Delisted | Director | — | $8.54 | — | $0 | 5 | 2019-06-24 |
| INCY | EVP, Chief Commercial Officer | 3,521 | $120.56 | $424.5K | -$22.72M | 16 | 2015-06-25 |
Recent Filings
81 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-16 | CYTK | Grant (A) | +151 | $12.5K | EDGAR |
| 2026-06-18 | MDGL | Grant (A) | +454 | $0 | EDGAR |
| 2026-06-01 | ACAD | Mixed | +8,107 | $0 | EDGAR |
| 2026-05-27 | CYTK | Grant (A) | +2,851 | $0 | EDGAR |
| 2026-04-15 | CYTK | Grant (A) | +191 | $12.5K | EDGAR |
| 2026-01-20 | CYTK | Grant (A) | +197 | $12.5K | EDGAR |
| 2025-11-12 | ACAD | Sell (S) | −30,000 | -$671.0K | EDGAR |
| 2025-11-10 | ACAD | Notice (144) | −30,000 | -$671.0K | EDGAR |
| 2025-08-20 | CYTK | Grant (A) | — | $0 | EDGAR |
| 2025-06-24 | MDGL | Grant (A) | +715 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.